HIV Pricing Strategies in the US and UK

Introduction

This brief provides an overview of HIV drug pricing strategies in the US and UK. The US market represents the largest and most interesting market for the pharmaceutical industry. The UK market is also profitable to the pharmaceutical industry, but is constrained by restrictions set by the Pharmaceutical Pricing and Regulation Scheme. 

Scope

Competition pricing strategies employed by HIV drug manufacturers are discussed 

Analysis of current price points of HIV drugs in the US and UK is provided 

BMS versus GSK pricing strategies 

Consolidation of Abbott’s HIV portfolio and its pricing 

Report Highlights

Pricing strategies between the US and UK differ in price points set for reformulated and novel drugs, for example BMS' Videx and Videx EC, GlaxoSmithKline's Combivir and Trizivir.  

Roche’s Fuzeon has been priced at $20,500 within the EU. Datamonitor anticipates that the US price will be even higher, thereby potentially limiting patient and physician uptake.  

HIV companies can afford to set high price points for novel classes of antiretrovirals, but only if product differentiation can be shown and superior efficacy proven 

Reasons to Purchase

Benchmark your HIV pricing strategies against current industry practice 

Optimize pricing strategy and ensure optimal patient uptake 

Publisher: Datamonitor Infectious Diseases Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases.html#a171